An In-Depth Analysis of Covid-19 Medications and Vaccination with A Focus on Side Effects

Jishnu  Banerjee; Rajdeep  Ghosh; Ananya  Paul; Soumyajit  Banik; Sumit  Halder; Joy Sarkar

doi:10.55489/njcm.141120233243

Authors

Jishnu Banerjee Ramakrishna Mission Vivekananda Centenary College, Rahara, India https://orcid.org/0000-0002-5377-0848
Rajdeep Ghosh M.R. Bangur Super Speciality Hospital, Kolkata, India https://orcid.org/0000-0002-0072-2500
Ananya Paul Chandigarh University, Ludhiana, India https://orcid.org/0000-0002-6828-0542
Soumyajit Banik Diamond Harbour Government Medical College and Hospital, Diamond Harbour, India
Sumit Halder Diamond Harbour Government Medical College and Hospital, Diamond Harbour, India https://orcid.org/0000-0002-4602-9365
Joy Sarkar Dinabandhu Andrews College, Kolkata, India

DOI:

https://doi.org/10.55489/njcm.141120233243

Keywords:

COVID-19, Drugs, Side Effects, Treatments, Vaccines

Abstract

Background: A pandemic threat to public health has been posed by the SARS-CoV-2 outbreak. To deal with the severe situation caused by this outbreak, medications were used, but we weren't thinking about the potential negative effects. This review sought to evaluate the efficacy and safety of various medications in COVID-19 patients, as well as the present state of medications and their adverse effects.

Methods: Several literature and databases were searched and analysed properly from 2020 to 2022 to find the relevant databases on the usage of proper medications.

Results: During COVID-19, many antivirals, antibiotics, and conventional drug therapy were in high demand. Many antivirals, including Remdesivir and Ritonavir, were tried, but they had a number of adverse effects, including hypokalaemia, headaches, and nausea. Another issue with the use of drugs in this pandemic is antibiotic resistance. Since vaccines are relatively new, adverse symptoms like fever, discomfort, chills, tiredness, nausea/vomiting, headache, and insomnia have so far been reported.

Conclusion: This analysis outlines a progressive change in the medical community, where simple treatment procedures have shown to be more successful than those using many drugs, producing better patient results. This indicates a shift in medical practice toward more simplified and effective modes of care.

References

Bhattacharyya P, Das S, Aich S, et al. COVID-19: Morphology and mechanism of the SARS-CoV-2, global outbreak, medication, vac-cines and future of the virus. Frontiers in Bioscience - Elite 2021; 13: 272-290. DOI: 10.52586/E884. Doi: https://doi.org/10.52586/E884 PMid:34937314

Dhama K, Patel SK, Pathak M, et al. An Update on SARS-COV-2/COVID-19 with Particular Reference on Its Clinical Pathology, Patho-genesis, Immunopathology and Mitigation Strategies - A Review. Travel Medicine and Infectious Disease 2020; 37: 101755. Doi: https://doi.org/10.1016/j.tmaid.2020.101755 PMid:32479816 PMCid:PMC7260597

Abou Ghayda R, Lee KH, Han YJ, et al. The global case fatality rate of coronavirus disease 2019 by continents and national income: A meta‐analysis. Journal of Medical Virology 2022; 94(6): 2402-2413. Doi: https://doi.org/10.1002/jmv.27610 PMid:35099819 PMCid:PMC9015248

Mohapatra RK, Kuppili S, Kumar Suvvari T, et al. SARS-CoV-2 and its variants of concern including Omicron: A never ending pan-demic. Chemical Biology & Drug Design 2022; 99: 769-788. Doi: https://doi.org/10.1111/cbdd.14035 PMid:35184391 PMCid:PMC9111768

Nutho B, Mahalapbutr P, Hengphasatporn K, et al. Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Corona-virus 2019? Atomistic Insights into the Inhibitory Mechanisms. Biochemistry 2020; 59: 1769-1779. Doi: https://doi.org/10.1021/acs.biochem.0c00160 PMid:32293875

Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. New England Journal of Medicine 2020; 382: 1787-1799. Doi: https://doi.org/10.1056/NEJMoa2001282 PMid:32187464 PMCid:PMC7121492

Cheng VCC, Chan JFW, To KKW, et al. Clinical management and infection control of SARS: lessons learned. Antiviral Res 2013; 100: 407-419. Doi: https://doi.org/10.1016/j.antiviral.2013.08.016 PMid:23994190 PMCid:PMC7132413

Matarrese P, Gambardella L, Cassone A, et al. Mitochondrial membrane hyperpolarization hijacks activated T lymphocytes toward the apoptotic-prone phenotype: homeostatic mechanisms of HIV protease inhibitors. J Immunol 2003; 170: 6006-6015. Doi: https://doi.org/10.4049/jimmunol.170.12.6006 PMid:12794128

Hassanipour S, Arab-Zozani M, Amani B, et al. The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. Scientific Reports 2021 11:1 2021; 11: 1-11. Doi: https://doi.org/10.1038/s41598-021-90551-6 PMid:34040117 PMCid:PMC8155021

Arshad S, Kilgore P, Chaudhry ZS, et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospital-ized with COVID-19. International Journal of Infectious Diseases 2020; 97: 396-403. Doi: https://doi.org/10.1016/j.ijid.2020.06.099 PMid:32623082 PMCid:PMC7330574

Sultana J, Cutroneo PM, Crisafulli S, et al. Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines. Drug Saf 2020; 43: 691-698. Doi: https://doi.org/10.1007/s40264-020-00976-7 PMid:32696429 PMCid:PMC7371963

Lode HM, Schmidt-Ioanas M. Moxifloxacin: Update and perspectives after 8 years of usage. Expert Rev Respir Med 2008; 2: 443-453. Doi: https://doi.org/10.1586/17476348.2.4.443 PMid:20477208

Caeiro JP, Iannini PB. Moxifloxacin (Avelox®): A novel fluoroquinolone with a broad spectrum of activity. Expert Rev Anti Infect Ther 2003; 1: 363-370. Doi: https://doi.org/10.1586/14787210.1.3.363 PMid:15482134

Caballero E, Cárdenas E, Gurucharri N, et al. Moxifloxacin. Rev Med Univ Navarra 2000; 44: 53-60. Doi: https://doi.org/10.15581/021.6770

Damanhouri ZA, Alkreathy HM, Ali AS, et al. The potential role of Fluoroquinolones in the management of Covid-19 a rapid review. Journal of Advanced Pharmacy Education and Research 2021; 11: 125-134. Doi: https://doi.org/10.51847/FE1iOIPTwD

Horowitz HW. Doxycycline Revisited: An Old Medicine for Emerging Diseases. Arch Intern Med 1998; 158(2): 192-193. Doi: https://doi.org/10.1001/archinte.158.2.192-a PMid:9448562

Narendrakumar L, Joseph I, Thomas S. Potential effectiveness and adverse implications of repurposing doxycycline in COVID-19 treatment. Expert Review of Anti-Infective Therapy 2020; 19(8): 1001-1008. Doi: https://doi.org/10.1080/14787210.2021.1865803 PMid:33322952

Papp-Wallace KM, Endimiani A, Taracila MA, et al. Carbapenems: Past, present, and future. Antimicrob Agents Chemother 2011; 55(11): 4943-4960. Doi: https://doi.org/10.1128/AAC.00296-11 PMid:21859938 PMCid:PMC3195018

Eid RA, Elgendy MO, El-Gendy AO, et al. Efficacy of ceftazidime and cefepime in the management of COVID-19 patients: Single center report from Egypt. Antibiotics 2021; 10: 1-11. Doi: https://doi.org/10.3390/antibiotics10111278 PMid:34827216 PMCid:PMC8614536

Ahmed MH, Hassan A. Dexamethasone for the Treatment of Coronavirus Disease (COVID-19): a Review. SN Compr Clin Med 2020; 2(12): 2637-2646. Doi: https://doi.org/10.1007/s42399-020-00610-8 PMid:33163859 PMCid:PMC7599121

Mohapatra RK, Kuppili S, Suvvari TK, et al. SARS-CoV-2 and its variants of concern including Omicron: A never ending pandemic. Chem Biol Drug Des 2022; 99(5): 769-788. Doi: https://doi.org/10.1111/cbdd.14035 PMid:35184391 PMCid:PMC9111768

Temple C, Hoang R, Hendrickson RG. Toxic Effects from Ivermectin Use Associated with Prevention and Treatment of Covid-19. New England Journal of Medicine 2021; 385(23): 2197-2198. Doi: https://doi.org/10.1056/NEJMc2114907 PMid:34670041 PMCid:PMC8552535

Therapeutics and COVID-19: living guideline, https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2022.2 (accessed 24 June 2023).

PIB Delhi. DCGI approves anti-COVID drug developed by DRDO for emergency use, https://pib.gov.in/PressReleasePage.aspx?PRID=1717007 (accessed 24 June 2023).

Kumar RN, Wu EL, Stosor V, et al. Real-World Experience of Bamlanivimab for Coronavirus Disease 2019 (COVID-19): A Case-Control Study. Clinical Infectious Diseases 2022; 74(1): 24-31. Doi: https://doi.org/10.1093/cid/ciab305 PMid:33846730 PMCid:PMC8083260

Rosenberg ES, Dufort EM, Udo T, et al. Association of Treatment with Hydroxychloroquine or Azithromycin With In-Hospital Mor-tality in Patients With COVID-19 in New York State. JAMA 2020; 323(24): 2493-2502. Doi: https://doi.org/10.1001/jama.2020.8630 PMid:32392282 PMCid:PMC7215635

Annane D, Heming N, Grimaldi-Bensouda L, et al. Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study. EClinicalMedicine 2020; 28: 100590. Doi: https://doi.org/10.1016/j.eclinm.2020.100590 PMid:33173853 PMCid:PMC7644240

Bastard P, Rosen LB, Zhang Q, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 2020; 370(6515). 1-12. Doi: https://doi.org/10.1126/science.abd4585 PMid:32972996 PMCid:PMC7857397

Leisman DE, Ronner L, Pinotti R, et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med 2020; 8(12): 1233-1244. Doi: https://doi.org/10.1016/S2213-2600(20)30404-5 PMid:33075298

Heming N, Sivanandamoorthy S, Meng P, et al. Immune effects of corticosteroids in sepsis. Front Immunol 2018 Doi: https://doi.org/10.3389/fimmu.2018.01736 PMid:30105022 PMCid:PMC6077259

Miyamasu M, Misaki Y, Izumi S, et al. Glucocorticoids inhibit chemokine generation by human eosinophils. Journal of Allergy and Clinical Immunology 1998; 101: 75-83. Doi: https://doi.org/10.1016/S0091-6749(98)70196-4 PMid:9449504

Pype JL, Dupont LJ, Menten P, et al. Expression of monocyte chemotactic protein (MCP)-1, MCP-2, and MCP-3 by human airway smooth-muscle cells. Modulation by corticosteroids and T-helper 2 cytokines. Am J Respir Cell Mol Biol 1999; 21: 528-536. Doi: https://doi.org/10.1165/ajrcmb.21.4.3660 PMid:10502563

Cronstein BN, Kimmel SC, Levin RI, et al. A mechanism for the antiinflammatory effects of corticosteroids: the glucocorticoid recep-tor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. Proc Natl Acad Sci U S A 1992; 89: 9991-9995. Doi: https://doi.org/10.1073/pnas.89.21.9991 PMid:1279685 PMCid:PMC50263

Kang BY, Song YJ, Kim KM, et al. Curcumin inhibits Th1 cytokine profile in CD4+ T cells by suppressing interleukin-12 production in macrophages. Br J Pharmacol 1999; 128: 380-384. Doi: https://doi.org/10.1038/sj.bjp.0702803 PMid:10510448 PMCid:PMC1571646

Zaidi AK, Dehgani-Mobaraki P. The mechanisms of action of ivermectin against SARS-CoV-2-an extensive review. The Journal of Antibiotics 2021 75:2 2021; 75: 60-71. Doi: https://doi.org/10.1038/s41429-021-00491-6 PMid:34931048 PMCid:PMC8688140

Zhang C, Wu Z, Li JW, et al. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents 2020; 55(5): 105954. Doi: https://doi.org/10.1016/j.ijantimicag.2020.105954 PMid:32234467 PMCid:PMC7118634

Mantha M, Suvvari T, Corriero A. 2-Deoxy-D-glucose as an armament against COVID-19: The key to return to normality? Biomedi-cal and Biotechnology Research Journal (BBRJ) 2021; 5: 347-348. Doi: https://doi.org/10.4103/bbrj.bbrj_94_21

Ganesh R, Philpot LM, Bierle DM, et al. Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients with Mild to Moderate Coronavirus Disease 2019. J Infect Dis 2021; 224: 1278-1286. Doi: https://doi.org/10.1093/infdis/jiab377 PMid:34279629 PMCid:PMC8344643

COVID-19 vaccines, https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines (accessed 26 june 2023).